Drug Candidate Repairs Motor/Sensory Function in Stroke
Source: Streetwise Reports��(7/29/22)
Shares of NervGen Pharma Corp. traded 28% higher yesterday after the company reported that, in a landmark pre-clinical animal study, its NVG-291-R demonstrated significant functional repair to damage from ischemic stroke seven days following the event. More >

Oil & Gas Services Co. Posts 90% Increase in Q2 Revenues
Source: Streetwise Reports��(7/29/22)
Energy industry service company Mammoth Energy Services Inc.'s shares traded 22% higher after the company reported Q2/22 financial results that included significant increases in quarterly revenue, net income, and adjusted EBITDA. More >

Energy Co. Looks for Cash Producing Oil & Gas Assets in Africa
��(7/29/22)
Tenaz Energy Corp. reported it was unsuccessful in obtaining the number of votes needed from SDX Energy Plc.'s shareholders to acquire the company. The firm continues to search for other oil and gas assets to acquire in North Africa and the Middle East that are congruent with its high free cash flow generation strategy. Research Capital Corp. advised in a research note that it is maintaining its Speculative Buy rating and CA$5.00 Target Price on the company.
More >

Val-d’Or Junior Finds Anomalies at MoGold
Source: Streetwise Reports��(7/28/22)
Geophysical surveys often reveal secrets just below the surface. One junior explorer operating in Quebec’s prolific Val d’Or mining camp has found a few of those secrets and it’s ready to drill them to see if a secret or two could become something much more valuable. More >

Junior Says ESG Is More Than an Acronym
Source: Streetwise Reports��(7/28/22)
This junior is trying new ways to involve the local population in its project, hoping to take “environmental, social, and governance” considerations to a new level. More >

Junior Hits High-Grade Silver in Colombia
Source: Streetwise Reports��(7/28/22)
Outcrop Silver & Gold Corp., on its way to a maiden resource estimate at its Colombian flagship project, says it has returned its thickest and highest-grade intercepts yet. More >

Additional Study Review Reveals Patients Coughed Much Less
Source: Streetwise Reports��(7/28/22)
A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough — only to learn that it treated chronic cough far better than first thought. More >

Biotech Co. Granted New Patent for Breast Cancer Vaccine
��(7/27/22)
Last Thursday, Anixa Biosciences Inc. announced that the USPTO granted an extension for the firm's patented breast cancer vaccine technology. H.C. Wainwright & Co. LLC advised that this action strengthens the company's IP portfolio and therefore it is reiterating its Buy rating on Anixa. More >

Miner to Finance Alaska Project with $60M Royalty Deal
Source: Streetwise Reports��(7/27/22)
Shares of Northern Dynasty Minerals Ltd. traded more than 22% higher after the Vancouver mining firm reported it entered into a life-of-mine royalty agreement for non-core metals which may provide up to $60 million in proceeds. More >

Biopharma Co. Signs Exclusive License Deal for Ricin Antigen
Source: Streetwise Reports��(7/27/22)
Shares of Soligenix Inc. traded 8% higher after the company reported it formed a strategic global partnership to supply SERB Pharmaceuticals with its novel ricin antigen for use in developing a therapeutic treatment against ricin poisoning. More >

Biomedical Firms Merger Makes Programming Cells Easier
Source: Streetwise Reports��(7/26/22)
Shares of Zymergen Inc. traded 16% higher after the company reported it agreed to be acquired by Ginkgo Bioworks Inc. in an all-stock transaction valued at $300 million. More >

Cancer Co.'s Price Target Adjusted After Reverse Stock Split
��(7/25/22)
Late clinical-stage biopharmaceutical company Cellectar Biosciences Inc. very recently underwent a one for 10 reverse stock split. ROTH Capital Partners LLC advised that it has adjusted its forward projections for the firm and adjusted its 12-month price target to $40/share. More >

Franco and Royal Make Major Investments
Source: Adrian Day��(7/25/22)
Expert Adrian Day discusses recent purchases from two royalty companies, as well as preliminary quarterly reports from several gold companies that he considers top buys right now. More >

Radiotherapy Co. On-Track With Two Clinical Trials
��(7/24/22)
Plus Therapeutics Inc. is developing novel radiotherapy treatments for several rare cancer targets including glioblastoma and leptomeningeal metastases. H.C. Wainwright & Co. advised in a research note that it is reiterating its Buy rating on the company as it expects that upcoming data from two key trials for the firm's RNL-based treatments could provide a major catalyst for the stock in H2/22. More >

Pro Athlete Benefits From Co.'s Wound Treatment Device
Source: Streetwise Reports��(7/22/22)
Shares of SANUWAVE Health Inc. traded 12% higher after the company reported it successfully treated legendary football player Jim McMahon Jr. with its ENERGY FIRST system. More >

Medical Device Firm Maintains Growth Momentum in Q2/22
��(7/21/22)
electroCore Inc.'s Q2/22 and H1/22 revenues are up quarter over quarter and year over year, respectively, and the upward trend is expected to continue through year-end 2022, noted an H.C. Wainwright & Co. report. More >

Amazon Makes $3.9B Bid for Virtual Primary Care Co.
Source: Streetwise Reports��(7/21/22)
Shares of One Medical traded nearly 70% higher after the company reported it agreed to be acquired by Amazon Inc. for $18.00 per share in an all-cash deal valued at $3.9 billion. More >

Biotech Co.'s Phase 3 Trial First to Get Grant
Source: Streetwise Reports��(7/20/22)
A revenue-generating junior biotech company based in the U.K. has become the first public company to be approved for a government grant to fund most of a Phase 3 study exploring the use of psychedelics to treat alcohol use disorder. It could be a catalyst for the share price. More >

Drug Repurposing Co. Provides Opportunity for High Rewards
��(7/20/22)
Vancouver-based pharmaceutical development firm Algernon Pharmaceuticals Inc. recently reported topline data from a Phase 2a trial of ifenprodil in IPF patients with chronic cough that met its endpoint and demonstrated promising initial efficacy. Research Capital Corp. advised that it is maintaining its CA$25.00/share price target and "Speculative Buy" rating on the company. More >

Expert Says the Tide Has Gone Out
Source: Michael J. Ballanger��(7/20/22)
Expert Michael Ballanger reviews the current market cycle, Elon Musk's impact on the stock market, and reveals the stock he says has a positive outlook amidst the chaotic backdrop of summer 2022. More >

Mining Co. Forms JV to Manage Key NewRange Materials Assets
Source: Streetwise Reports��(7/20/22)
PolyMet Mining Corp. shares traded nearly 8% higher after the company reported it entered into a joint-venture deal with Teck Resources Ltd. to develop copper, nickel, cobalt, and platinum group metals resources at the NorthMet and Mesaba properties in Minnesota. More >

Trial Results Show New Drug Improves Dry Eye Symptoms
Source: Matthew Caufield ��(7/19/22)
These study data from Aldeyra Therapeutics Inc. solidified the therapeutic's path to filing a new drug application, potentially in Q3/22, noted an H.C. Wainwright & Co. report. More >

Uranium Co. Reports Solid Drill Results at Alligator River
Source: Streetwise Reports��(7/19/22)
Shares of Vimy Resources Ltd. traded 19% higher after the company reported positive results from the first two diamond drill holes at its Alligator River Project in Australia's Northern Territory. The company said it plans to prepare a mineral resource update for its Angularli Deposit in late 2022. More >

Tectonic Metals Closes CA$2.3M Private Placement
Source: The Critical Investor��(7/19/22)
The Critical Investor explains why major shareholders like Crescat Capital "are stepping up once again ... but this time increasing their ownership in Tectonic even more" as everyone eagerly awaits the results from Seventymile.
More >

Satellite Co. Posts Record Revenue in Q2 From Aerospace Firm
Source: Streetwise Reports��(7/19/22)
Shares of Sidus Space Inc. traded 37% higher after the satellite technology company reported it has expanded the scope of its working relationship and increased deliverables to Teledyne Technologies Inc. Sidus stated that revenues registered under its contracts with Teledyne in Q2/22 were the highest amounts earned over the course of its four-year relationship with that company. More >